<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184467</url>
  </required_header>
  <id_info>
    <org_study_id>KG 6/2016</org_study_id>
    <nct_id>NCT03184467</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GemVax &amp; Kael</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GemVax &amp; Kael</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed as a multi-center, randomized, double-blind,
      placebo-controlled, parallel design, prospective, phase II clinical trial.

      An eligible subject who meets inclusion and exclusion criteria is randomly assigned to three
      groups: study group 1 (GV1001 0.56 mg), study group 2 (GV1001 1.12 mg) or placebo group. A
      randomized subject is administered either GV1001 or placebo in a total of 14 times and will
      be evaluated for the efficacy and safety at week of 24.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GV1001 0.56 mg, 1.12 mg or placebo is subcutaneously administered once weekly schedule for 4
      weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of
      administration is 14 times.

        1. Control group (placebo): 30 subjects

        2. Study group 1 (GV1001 0.56 mg): 30 subjects

        3. Study group 2 (GV1001 1.12 mg): 30 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SIB (Severe Impairment Battery)</measure>
    <time_frame>week 24</time_frame>
    <description>Change in SIB compared to the baseline and week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>K-MMSE (Korean-Mini-Mental State Examination)</measure>
    <time_frame>week 24</time_frame>
    <description>Change in K-MMSE compared to the baseline and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDR-SOB (Clinical Dementia Rating-Sum of Box)</measure>
    <time_frame>week 24</time_frame>
    <description>Change in CDR-SOB compared to the baseline and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPI (Neuropsychiatric Inventory)</measure>
    <time_frame>week 24</time_frame>
    <description>Change in NPI compared to the baseline and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GDS (Global Deterioration Scale)</measure>
    <time_frame>week 24</time_frame>
    <description>Change in GDS compared to the baseline and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADCS-ADL-severe (Alzheimer's Disease Cooperative Study-Activities of Daily Living scale-severe)</measure>
    <time_frame>week 24</time_frame>
    <description>Change in ADCS-ADL-severe compared to the baseline and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC-plus (Clinician Interview-Based Impression of Change-Plus)</measure>
    <time_frame>week 24</time_frame>
    <description>Change in CIBIC-plus compared to the baseline and week 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 0.9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GV1001 0.56 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GV1001 1.12 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 0.9%</intervention_name>
    <description>Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>NS 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GV1001 0.56 mg</intervention_name>
    <description>GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.</description>
    <arm_group_label>Study group 1</arm_group_label>
    <other_name>Tertomotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GV1001 1.12 mg</intervention_name>
    <description>GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.</description>
    <arm_group_label>Study group 2</arm_group_label>
    <other_name>Tertomotide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 55 to 85 years of age

          2. A patient who satisfies diagnostic criteria for dementia in DSM-IV

          3. Probable Alzheimer's disease in NINCDS-ADRDA

          4. K-MMSE â‰¤ 19 at screening and randomization visit

          5. GDS 5~6 stage

          6. MRI or CT scan within 12 months prior to screening visit that proves Alzheimer's
             disease without any other disease that may cause dementia

          7. A patient taking stable doses of donepezil for more than 3 months before screening
             visit

          8. A patient who are able to visit a hospital (including inpatient and outpatient based)
             and receive cognitive and other tests

          9. A patient with a caregiver who can accompany all visits and supervise the subject's
             compliance with the procedures and study drug prescribed in the protocol, and provide
             detailed information about the patient

         10. Written informed consent by a patient or legal representative

        Exclusion Criteria:

          1. Any other cause of dementia shown by CT / MRI findings and neurological examination
             within 12 months of screening visit

               -  Possible, probable or definite vascular dementia according to the NINDS-AIREN

               -  Other central nervous system diseases that may cause cognitive impairment
                  (cerebrovascular disease including cerebrovascular dementia, Parkinsonism,
                  Huntington's disease, subdural hematoma, normal pressure hydrocephalus, brain
                  tumor, Creutzfeldt-Jakob disease, etc.)

               -  Neurological deficits such as delusions, delirium, epilepsy

          2. Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH)
             results are thought to contribute to the severity of dementia or cause dementia

          3. A patient who are considered ineligible for this study by investigator due to
             concurrent or history of significant psychiatric conditions (eg. schizophrenia or
             bipolar affective disorder)

          4. A patient with a history of known or suspected seizures including febrile seizures, a
             history of significant head trauma with loss of consciousness or recent
             unconsciousness that is not explained

          5. A patient with acute or unstable cardiovascular disease, active peptic ulcer,
             uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any
             medical condition that may interfere with the completion of clinical trials

          6. Hypersensitivity to investigational medicinal products

          7. History of alcohol, substance abuse or dependence (except nicotine dependence) within
             the last 2 years

          8. Concurrent malignancies or invasive cancers diagnosed within the past 5 years except
             for non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ
             carcinoma of the uterine cervix or non-metastatic prostate cancer

          9. Renal impairment (creatinine clearance (CLcr) &lt;30 mL / min)

         10. Severe liver dysfunction (ALT or AST&gt; 2 times the upper limit of normal)

         11. A patient taking other drugs other than donepezil to treat Alzheimer's disease or
             other cognitive impairment

         12. A patient taking other drugs other than anticholinergic drugs, cholinergic drugs
             (local usages are allowable, such as pilocarpine eye drops), antidepressants
             (tricyclic antidepressant, MAO inhibitor) antipsychotics, donepezil to treat
             Alzheimer's disease

         13. Women at childbearing age who do not consent using medicinally acceptable
             contraception (such as surgical sterilization, intrauterine contraceptive device,
             condom or diaphragm, an injectable or inserted contraceptive) during the study

         14. Pregnancy or breast feeding

         15. A patient who participated in other clinical trials within 4 weeks prior to this study

         16. 35 kg weight or below

         17. A patient who had experienced this study drug

         18. A patient who had participated in a clinical trial for Alzheimer dementia vaccine
             within last 6 months

         19. Any other patients who are considered to be ineligible for this study by an
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Gon Song, MD., PhD.</last_name>
    <role>Study Director</role>
    <affiliation>GemVax &amp; Kael</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moonhwan Do, Bachelor</last_name>
    <phone>+82 70 4367 2714</phone>
    <email>mdo@gemvax.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaeyoung Park, Bachelor</last_name>
    <phone>+82 70 4738 9721</phone>
    <email>jypark@kaelgemvax.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Gyunggi-do</state>
        <zip>11923</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Ho Koh, MD, PhD.</last_name>
      <email>ksh213@hanyang.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GV1001</keyword>
  <keyword>Alzheimer Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

